Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
5.28
+0.05 (0.96%)
Nov 20, 2024, 4:00 PM EST - Market closed

Company Description

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications.

Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.

Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018.

Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Outlook Therapeutics, Inc.
Outlook Therapeutics logo
Country United States
Founded 2010
IPO Date May 13, 2016
Industry Biotechnology
Sector Healthcare
Employees 24
CEO C. Trenary

Contact Details

Address:
Building F, Suite 320
Iselin, New Jersey 08852
United States
Phone 609 619 3990
Website outlooktherapeutics.com

Stock Details

Ticker Symbol OTLK
Exchange NASDAQ
Fiscal Year October - September
Reporting Currency USD
CIK Code 0001649989
CUSIP Number 69012T206
ISIN Number US69012T3059
Employer ID 38-3982704
SIC Code 2836

Key Executives

Name Position
C. Russell Trenary III President, Chief Executive Officer and Director
Ralph H. Thurman Independent Executive Chairman
Lawrence A. Kenyon CPA Executive Vice President, Chief Financial Officer, Treasurer, Company Secretary and Director
Jeffrey Evanson Chief Commercial Officer
Joel Prieve Senior Vice President of Licensing and M&A
Dr. Surendra Sharma M.D. Senior Vice President of Medical Affairs
Dr. Jennifer M. Kissner Ph.D. Senior Vice President of Clinical Development and Regulatory Affairs
Jedd Comiskey Senior Vice President - Head of Europe

Latest SEC Filings

Date Type Title
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 7, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Aug 14, 2024 S-8 Securities to be offered to employees in employee benefit plans
Aug 14, 2024 10-Q Quarterly Report
Aug 14, 2024 8-K Current Report
Jul 8, 2024 8-K Current Report
Jun 26, 2024 DEF 14A Other definitive proxy statements
Jun 14, 2024 PRE 14A Other preliminary proxy statements
May 28, 2024 8-K Current Report
May 15, 2024 8-K Current Report